# NCT05126472 (NCT05126472)

> Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05126472
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Non-muscle Invasive Bladder Cancer
- Interventions: anti-CD40 antibody 2141-V11; anti-CD40 antibody 2141-V11; anti-CD40 antibody 2141-V11; Intravesical Gemcitabine; Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
- Enrollment: 115
- Primary outcome: MTD/RP2D (Cohort A)
- Primary outcome: Reported number of adverse events from baseline (start of 2141-V11 administration) up until the last follow-up visit after 2141-V11 administration (Cohort B)
- Primary outcome: recurrence-free survival (RFS) Cohort B Part 2
- Primary outcome: Progression of disease

## Indexed commentary on NCT05126472 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05126472
